Story
Eli Lilly Named Top Pharma Pick by Jefferies on Strong Earnings, Raised Outlook

Jefferies has identified Eli Lilly and Co. (LLY) as its top pick in the large-cap pharmaceutical sector, raising its price target on the stock to $1,440 per share. The updated target, representing an approximate 29% upside from its current price, follows a robust second-quarter performance and increased financial guidance from the drugmaker.
Analyst Boosts Outlook on Earnings Beat
In a recent note, Jefferies analyst Akash Tewari reiterated a Buy rating on Eli Lilly, attributing the optimism to a significant outperformance in the second quarter. The company reported total revenues of approximately $23 billion, easily surpassing consensus estimates of $20.7 billion. Earnings per share (EPS) came in at $8.38, well ahead of the anticipated $6.68.
This strong financial performance was underpinned by surging demand for its key products, prompting the firm to raise its outlook. The analyst's new price target reflects confidence in the company's continued growth trajectory.
Mounjaro and Zepbound Drive Growth
The sales momentum was largely driven by the company's popular GLP-1 drugs for diabetes and weight management. According to Jefferies, sales for these key products exceeded market expectations:
Ad- Mounjaro: Exceeded estimates by 12%, generating approximately $9.94 billion in total revenue.
- Zepbound: Beat estimates by 6%, bringing in $4.93 billion in revenue.
Eli Lilly's new oral GLP-1 product, Foundayo (orforglipron), also contributed $98 million in its initial launch quarter. The report highlighted the company's dominant market position, noting it holds approximately 60.9% of the U.S. incretin analog market and 54.9% of the international incretin market.
Upgraded Guidance and Market Expansion
Following the strong quarter, Eli Lilly increased its fiscal year 2026 revenue guidance to a range of $85 billion to $87 billion, up from its previous forecast of $82-85 billion. Jefferies views this updated guidance as conservative, with its own model projecting revenues above the high end at $88.5 billion.
Market access continues to expand, with the Medicare Bridge Program potentially adding 20 million eligible patients in the U.S. since its July 1 start. Furthermore, Foundayo recently received approval in the United Kingdom for both weight management and type 2 diabetes. Other investment firms, including Wells Fargo and BMO Capital, have also raised their price targets on Eli Lilly following the results.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.